Depo-Provera April 29, 2026 · 13 min read

Depo-Provera Lawsuit Settlement Amounts: How Much Could Your Case Be Worth in 2026?

Attorney projections for Depo-Provera meningioma cases range from $150,000 to $1.5 million or more, depending on tumor grade, surgical history, and the severity of neurological damage. But here is what many articles won't tell you upfront: as of April 2026, not a single case has settled. The litigation is still in pre-trial. Understanding why — and understanding what will drive settlement values when they do materialize — is the most important thing a potential plaintiff can know right now.

$150K–$1.5M+

Attorney-projected settlement range (projections only)

3,490

Federal MDL cases pending as of April 5, 2026[1]

Dec 7, 2026

First bellwether trial: Blonski v. Pfizer[2]

~10,000

Estimated unfiled "warehoused" claims awaiting court rulings

In This Article

  1. 1. Important Disclaimer: No Settlements Finalized as of April 2026
  2. 2. The Settlement Tier System: How Plaintiff Attorneys Value Cases
  3. 3. Factors That Determine Which Tier Your Case Falls Into
  4. 4. Comparable Pharmaceutical Mass Tort Settlements
  5. 5. Attorney Fees and What You Actually Take Home
  6. 6. Why Settlements Haven't Happened Yet — The Mass Tort Timeline
  7. 7. Pfizer's Financial Exposure and Capacity to Settle
  8. 8. What You Can Do Now to Maximize Your Case Value
  9. 9. Frequently Asked Questions
  10. 10. Sources & References

Important Disclaimer: No Settlements Finalized as of April 2026

Before discussing any numbers, this must be stated plainly: as of April 2026, there are no finalized settlements in the Depo-Provera meningioma litigation. Pfizer has not settled a single case. No global settlement fund has been announced. No per-claim settlement matrix has been agreed upon by the parties. Any dollar figure you read — including the ranges discussed in this article — represents attorney projections and estimations based on injury severity comparisons and precedent from other pharmaceutical mass torts. They are not guarantees, offers, or agreements.

Why Projections Exist Before Any Settlement

Plaintiff attorneys must assess case value before accepting clients — they work on contingency and bear all upfront costs. These projections are internal working estimates used to prioritize case intake and manage client expectations. They are not binding and should not be treated as promises.

The reason no settlements exist yet has everything to do with where the litigation currently stands in the normal mass tort lifecycle. The Depo-Provera MDL — formally In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, before Judge M. Casey Rodgers in the Northern District of Florida — is in active pre-trial proceedings. As of April 2026, the parties are preparing for two pivotal hearings that will define the litigation's trajectory:

  • May 29, 2026: Deadline for Daubert challenge briefs — both Pfizer and plaintiffs submit arguments about whether the other side's expert witnesses should be allowed to testify at trial.
  • June 24–26, 2026: General causation Daubert hearing before Judge Rodgers — the court decides whether plaintiffs' scientific experts can testify that Depo-Provera causes meningioma. This is one of the most critical rulings in the entire litigation.
  • Pending: A ruling on Pfizer's federal preemption defense — a ruling that, if it goes against Pfizer, would eliminate its primary legal shield against failure-to-warn claims.
  • December 7–14, 2026: First bellwether trial — Blonski v. Pfizer Inc. — the first jury verdict in this litigation.

In mass tort litigation, meaningful settlement negotiations almost never begin before bellwether trial results give both sides hard data on jury sentiment. The first Blonski trial in December 2026 will be closely watched because a substantial plaintiff verdict would give plaintiffs enormous leverage — and the prospect of thousands more trials — making settlement far more attractive to Pfizer. This is the standard playbook for pharmaceutical mass torts, and the Depo-Provera litigation is following it precisely.

With that context established, let's examine how plaintiff attorneys currently project case values and what drives those projections.

The Settlement Tier System: How Plaintiff Attorneys Value Cases

Mass tort settlements almost never pay every plaintiff the same amount. Instead, attorneys and defendants negotiate a tiered settlement grid — a structured system that assigns different dollar ranges to different levels of injury severity. This approach mirrors what workers' compensation systems do with disability ratings, but the specific factors and dollar amounts are negotiated privately between plaintiff leadership (called the Plaintiffs' Steering Committee, or PSC) and the defendant's legal team.

Based on the injury profile of the Depo-Provera litigation and analogous pharmaceutical settlements, plaintiff attorneys currently project four general tiers. These are working estimates — not finalized terms — but they reflect the consensus range among experienced mass tort attorneys who are actively screening and signing Depo-Provera clients.

Tier 1 — Catastrophic / Maximum Severity

$650,000 – $1,500,000+

Tier 1 cases involve the most devastating outcomes — the cases where Depo-Provera's alleged harm has permanently altered or ended a woman's life. To qualify for this tier, a plaintiff typically must demonstrate most or all of the following:

  • WHO Grade II or Grade III tumor: Atypical or anaplastic meningiomas that are more aggressive, more likely to recur, and far harder to treat than the benign Grade I variety. Grade III meningiomas carry a significantly elevated mortality risk.
  • Multiple surgeries: Craniotomies are among the most dangerous and physically traumatic procedures in medicine. Patients who required two or more brain surgeries — often because the tumor recurred after the first resection — will present far stronger damages arguments than those who had a single successful procedure.
  • Major permanent neurological deficits: This category includes cortical blindness or significant vision loss, unilateral or bilateral hearing loss, severe and permanent cognitive impairment (memory loss, language deficits, executive function deterioration), intractable seizure disorders requiring ongoing anticonvulsant medication, and motor deficits ranging from weakness to full paralysis.
  • Wrongful death cases: Cases where a woman died from the meningioma, surgical complications, or related causes. These wrongful death claims include survival damages, loss of consortium claims by surviving spouses or children, and potentially punitive damages depending on state law.
  • Long-duration use and young age at onset: Plaintiffs who used Depo-Provera for ten or more years, particularly those who began use in their teens or early twenties and developed a tumor in their thirties or forties, will present powerful narrative arguments about a lifetime of missed opportunities and premature disability.

Example plaintiff profile: A 38-year-old woman who used Depo-Provera for 12 years beginning at age 19, developed a Grade II meningioma causing significant hearing loss and short-term memory impairment, required two surgeries including a revision craniotomy when the tumor recurred, and was forced to leave her career as a nurse. Her case would almost certainly be in Tier 1 territory.

Tier 2 — Significant Surgical Injury

$300,000 – $650,000

Tier 2 represents the core of the litigation — cases where surgery was necessary and where the plaintiff has documented, meaningful harm that has substantially altered her life, even if the outcome was not catastrophic. Most surgical meningioma cases will fall somewhere in this range.

  • Single craniotomy successfully completed: A craniotomy is open brain surgery involving removal of a section of the skull. Even a "successful" procedure carries significant risks — infection, bleeding, stroke, reaction to anesthesia — and requires weeks to months of recovery. Many patients experience lasting fatigue, cognitive changes, and personality shifts even after "successful" tumor removal.
  • Grade I tumor with surgical intervention: A benign meningioma that nonetheless required surgery because of its size, location, or the symptoms it was causing. These cases will be weaker on damages than Grade II/III cases but still substantial if surgery caused lasting effects.
  • Partial neurological deficits: Partial vision or hearing changes, mild-to-moderate cognitive slowing, occasional seizures managed with medication, balance or coordination problems, or persistent headaches. The deficits must be documented in medical records — self-reporting alone is insufficient.
  • Significant quality of life impact: Loss of employment or forced career change, inability to drive, restrictions on physical activity, documented depression or anxiety attributable to the diagnosis and treatment, and the psychological burden of living with the knowledge that a brain tumor could recur.

Example plaintiff profile: A 45-year-old teacher who used Depo-Provera for 7 years, was diagnosed with a Grade I meningioma that caused worsening headaches and balance problems, underwent a single successful craniotomy, and was left with mild but documented short-term memory difficulties that required accommodations at work.

Tier 3 — Non-Surgical Tumor Management

$150,000 – $300,000

Tier 3 cases involve plaintiffs who developed a confirmed meningioma but whose tumor was managed without open brain surgery. The injury is real and the causal link is the same — but the absence of surgical trauma limits the damages argument.

  • Radiation therapy (stereotactic radiosurgery / Gamma Knife): Radiation treatment for a meningioma is still a serious medical intervention, carries its own risks, and constitutes real harm. Patients who received radiosurgery — even without open craniotomy — have experienced significant disruption to their lives and have a strong liability argument.
  • Watchful waiting / active observation: Some meningiomas, particularly small Grade I tumors in stable locations, are managed with regular MRI surveillance rather than immediate intervention. While the harm is less acute, the ongoing anxiety, cost of repeated imaging, and risk of future intervention are real and compensable.
  • Managed but persistent symptoms: Headaches, mild cognitive changes, fatigue, or other symptoms that are documented in medical records but have not required surgical correction. The key here is documentation — symptom diaries, doctor visit notes, and specialist records that demonstrate the tumor is affecting daily life.
  • Ongoing treatment costs: Even non-surgical patients accumulate real economic damages through specialist visits, imaging, medications for symptom management, and the disruption of regular medical monitoring.

Example plaintiff profile: A 52-year-old administrative professional who used Depo-Provera for 5 years, was diagnosed with a small Grade I meningioma after complaining of recurring headaches, and whose neurologist placed her on a watch-and-wait protocol with MRI every six months. She has not had surgery but lives with persistent anxiety and attends multiple specialist appointments per year.

Tier 4 — Incidentally Discovered Asymptomatic Tumor

Under $150,000

Tier 4 represents the weakest category in the litigation — cases where a meningioma was discovered incidentally (typically found during imaging for an unrelated condition), has caused no symptoms, and requires no immediate treatment. Many experienced plaintiff firms will decline these cases entirely, not because liability is weaker (it is not — the causal argument is the same), but because the damages are so limited that the case may not generate enough recovery to justify the cost of litigation.

  • No symptoms attributable to the tumor: The plaintiff has no headaches, neurological changes, or other symptoms connected to the meningioma.
  • No treatment required to date: The treating neurologist has recommended observation only — no surgery, no radiation.
  • Future risk and anxiety: The strongest argument in these cases is the psychological burden of knowing you have a brain tumor and the ongoing cost of monitoring. Some attorneys characterize this as a present injury; others view it as too speculative for a strong damages claim.

Note: If you fall into this category and your tumor grows or becomes symptomatic, your tier classification can improve. Attorneys will typically advise monitoring clients with Tier 4 cases and re-evaluating if medical management changes.

The ranges above are aggregate projections. Within each tier, individual case values vary significantly based on the specific factors discussed in the next section. A Tier 2 plaintiff with particularly strong economic damages — a high-income earner who was forced to leave a high-salary career — could push toward the top of the Tier 2 range or potentially into Tier 1 territory. A Tier 1 plaintiff with limited documentation of neurological deficits might receive a value closer to the bottom of that tier.

Wondering where your case might fall in this system?

An attorney in our network can review your specific medical history, Depo-Provera use duration, and tumor diagnosis for free. No commitment required.

Get a Free Case Evaluation arrow_forward

Factors That Determine Which Tier Your Case Falls Into

Tier placement is not arbitrary. It flows from a detailed analysis of specific medical, economic, and factual factors. Here is how each major factor affects case value — and why.

1. WHO Tumor Grade (I, II, or III)

The World Health Organization classifies meningiomas on a three-point scale. Grade I (benign) meningiomas make up approximately 80% of all meningiomas and are slow-growing and generally well-defined. Grade II (atypical) meningiomas have a higher recurrence rate and more aggressive behavior. Grade III (anaplastic or malignant) meningiomas are the rarest but most dangerous, with behavior similar to aggressive brain cancers. The higher the grade, the greater the medical severity, the more intensive the required treatment, the more likely the tumor will recur, and the stronger the damages case. A Grade III diagnosis is almost always in Tier 1 territory regardless of other factors.

2. Whether Surgery Was Required and How Many Surgeries

This is one of the single most important damages factors. Open craniotomy is a serious surgical procedure with real risks — bleeding, stroke, infection, cognitive effects from anesthesia, and the physical trauma of having one's skull opened and brain tissue manipulated. Even a routine, successful craniotomy involves weeks of hospital recovery, months of rehabilitation, and permanent lifestyle changes for many patients. From a legal standpoint, each craniotomy adds significant documented harm. Plaintiffs who underwent multiple surgeries due to tumor recurrence represent some of the strongest cases in the litigation. Radiosurgery (Gamma Knife, CyberKnife) is a lesser but still significant procedure that adds meaningful value above watchful waiting cases.

3. Neurological Deficits and Their Permanence

Pain and suffering damages in personal injury cases are often described as "general damages" — the non-economic component of a claim. In meningioma cases, the strongest general damages arguments come from permanent neurological deficits: vision changes (including cortical blindness), hearing loss, cognitive impairment (memory, concentration, executive function), motor deficits, and seizure disorders requiring lifelong medication. The word "permanent" is critical — temporary symptoms resolve and have limited damages value, while permanent deficits documented by a neurologist carry substantially more weight. Attorney assessors will scrutinize medical records for whether deficits are attributed by the treating physician to the tumor or surgery, not just the patient's self-report.

4. Duration of Depo-Provera Use

Duration is critical to the causation argument. The landmark 2024 BMJ study found a statistically significant meningioma risk only in women who used Depo-Provera for one year or longer (odds ratio of 5.55), with no significant risk for shorter use.[3] The November 2025 TriNetX study similarly found concentrated risk in women with four or more years of exposure.[4] A woman who used Depo-Provera for two years has a plausible causation argument; a woman who used it for twelve years has an overwhelmingly stronger one. From a settlement matrix perspective, longer use duration typically corresponds to higher tier placement — not because duration itself is a damage, but because it significantly strengthens the plaintiff's ability to prove that Depo-Provera caused her specific tumor.

5. Age at First Use

The TriNetX study specifically identified patients who began using Depo-Provera after age 31 as having elevated meningioma risk.[4] This is a scientifically nuanced point — younger users appear to have some protective factors or different hormonal dynamics — and attorneys working on causation arguments will be watching how the June 2026 Daubert hearing addresses this subgroup. However, this does not mean users who started before age 31 have no case; it means age at first use is one of many factors weighed in the overall causation analysis. Users who started after 31 may have a somewhat stronger per-case causation argument.

6. Income and Lost Wages (Economic Damages)

Economic damages in personal injury cases cover quantifiable financial losses: lost wages from time missed at work, lost future earning capacity if disability is permanent, the cost of medical treatment (surgeries, hospitalization, radiation, medications, ongoing specialist visits), and future medical costs. A high-income plaintiff who was forced to leave her career due to cognitive deficits can claim substantially more economic damages than someone with the same medical presentation who was retired or had lower pre-injury earnings. Economic damages are calculated by expert economists and presented to the jury or settlement negotiators as documented, calculated figures rather than estimates.

7. Pain and Suffering Documentation

Non-economic damages — pain, suffering, emotional distress, loss of enjoyment of life — are subjective but very real components of meningioma claims. The better-documented these damages are, the higher the recovery. Attorneys advise clients to keep detailed symptom diaries, attend regular mental health counseling, and obtain documentation from family members who can attest to observable changes in the plaintiff's functioning and personality. Courts and juries respond to evidence of suffering that goes beyond medical charts — journals, testimony from loved ones, and expert psychiatric evaluations all contribute to this component of case value.

8. Caregiver Costs and Ongoing Treatment

Plaintiffs who required significant caregiver assistance during and after surgery — particularly those with mobility limitations or severe cognitive deficits — can claim professional caregiver costs and the value of unpaid family caregiving. Ongoing treatment costs (anti-seizure medications, follow-up MRI surveillance, neurologist visits, physical or cognitive rehabilitation) add to future damages calculations. A life care plan prepared by a qualified medical expert can quantify these future costs over the plaintiff's remaining life expectancy, adding substantial dollars to total case value.

Comparable Pharmaceutical Mass Tort Settlements

One of the most useful ways to project Depo-Provera settlement values is to examine how comparable pharmaceutical mass tort litigations resolved. While every litigation is different, and the specific facts of each case drive the final numbers, historical precedent provides a meaningful anchor for projections. Plaintiff attorneys examining the Depo-Provera litigation point consistently to the following comparison cases.

Yaz / Yasmin (Bayer) — Blood Clot Litigation

~$212,000–$220,000 per claim

Bayer resolved approximately 10,300 blood clot claims arising from its Yaz and Yasmin birth control pills for a total of approximately $2.04 billion — roughly $212,000 to $220,000 per claim. These claims involved serious cardiovascular injuries including deep vein thrombosis, pulmonary embolism, stroke, and gallbladder disease. Blood clot injuries, while serious, are generally more reversible and less permanently disabling than brain tumors requiring surgery. Plaintiff attorneys argue that meningioma brain tumor injuries — particularly those requiring craniotomy and resulting in permanent neurological deficits — are categorically more severe, supporting higher individual settlement values in the Depo-Provera litigation than the Yaz benchmark.

NuvaRing (Merck) — Blood Clot Litigation

~$50,000 per claim

Merck resolved approximately 2,000 NuvaRing blood clot claims for approximately $100 million — roughly $50,000 per claim. The NuvaRing settlement is often cited as a lower comparator precisely because the case pool was smaller, the injuries generally less severe than the Yaz/Yasmin cases, and Merck's negotiating leverage was stronger. The Depo-Provera litigation is significantly larger in case volume and involves brain tumor injuries of substantially greater severity than blood clots.

Essure (Bayer) — Permanent Device Complications

~$41,000 per claim

Bayer resolved approximately 39,000 Essure claims — a permanent birth control device linked to severe pelvic pain, device migration, and hysterectomy — for $1.6 billion, or approximately $41,000 per claim. The relatively low per-claim value reflects the extraordinary number of claimants (diluting the total pool) and the variable severity of injuries. The Essure comparison is most useful as a floor — the Depo-Provera litigation involves more severe injuries on a per-case basis, supporting higher individual values.

Talcum Powder (Johnson & J&J) — Ovarian Cancer

Individual verdicts exceeding $2 billion

The Johnson & Johnson talcum powder litigation offers perhaps the most compelling comparison because it involves cancer diagnoses — injuries with meaningful severity overlap with meningioma. Individual jury verdicts in the talcum powder litigation have exceeded $2 billion in some cases, though appellate courts have reduced many of these awards. J&J has pursued controversial bankruptcy strategies to limit its exposure, making a single clean settlement figure difficult to state. What is clear is that pharmaceutical litigation involving cancer-level injuries can generate extraordinary individual jury verdicts that pressure defendants into substantial settlement programs.

Why Meningioma Brain Tumor Injuries Support Higher Per-Case Values

Plaintiff attorneys argue — with justification — that intracranial meningioma injuries are more severe on a per-case basis than most injuries in comparable pharmaceutical settlements. Consider: a meningioma is a brain tumor that, when it requires surgery, necessitates open craniotomy — one of the most physically traumatic and medically risky procedures in medicine. Permanent neurological deficits from meningiomas (vision loss, hearing loss, cognitive impairment) are irreversible and affect every dimension of a person's life. By contrast, blood clot injuries, while serious, are often fully treatable with anticoagulation therapy and resolve without permanent disability in many cases. The injury severity gap between meningioma and blood clot cases is real, significant, and will be central to plaintiff attorneys' settlement negotiations with Pfizer.

If plaintiff-side projections prove accurate — and the litigation proceeds past the December 2026 bellwether to a larger settlement program — the Depo-Provera litigation could rank among the most significant pharmaceutical mass torts of the decade on a per-claimant basis.

Attorney Fees and What You Actually Take Home

Mass tort attorneys work on a contingency fee basis — meaning they charge no upfront fees and are only paid if and when your case resolves with a recovery. This structure makes mass tort litigation accessible to plaintiffs who could never afford to pay hourly legal fees to fight Pfizer. But it is essential to understand how the fee structure works before evaluating what a settlement is actually worth to you personally.

Standard Contingency Fee Range

In pharmaceutical mass tort cases, contingency fees typically range from 33% to 40% of gross recovery. The specific percentage is set out in your retainer agreement with your attorney, and it may vary based on the firm, the stage at which the case resolves (cases that settle before trial often carry lower fees than those that go to verdict), and the complexity of your specific case. In MDL settings, some courts also assess a common benefit fee — a percentage of each plaintiff's recovery that goes into a fund to compensate lead attorneys who do work that benefits all plaintiffs in the MDL, not just their individual clients. This common benefit assessment typically runs 5% to 8% and is taken before your individual attorney's contingency fee is calculated.

Case Costs and Expenses

In addition to attorney fees, litigation expenses are typically deducted from your gross settlement before you receive your net payment. In pharmaceutical mass torts, these costs can be substantial:

  • Expert witness fees: Causation experts (neuroradiologists, epidemiologists, oncologists, neurologists) who review your records and prepare reports may charge $15,000 to $50,000+ per case.
  • Medical record retrieval: Obtaining complete medical records from multiple providers, pharmacies, and hospitals can cost $500 to $2,000 per case.
  • Deposition costs: Court reporter fees, transcript preparation, and video recording for expert and fact witness depositions can reach $3,000 to $10,000 per case.
  • Filing and administrative fees: Court filing fees, process server fees, and administrative costs of maintaining your case in the MDL system.

In most cases, your attorney advances these costs and recovers them from the settlement proceeds — meaning you pay nothing out of pocket unless your case resolves favorably. Make sure your retainer agreement is clear about whether costs are deducted before or after the contingency fee percentage is calculated, as this can affect your net recovery.

Illustrative Net Recovery Calculation (Hypothetical Tier 2 Case)

Gross settlement amount (hypothetical Tier 2 midpoint) $475,000
Common benefit fee assessment (6%) −$28,500
Attorney contingency fee (33% of net after common benefit) −$148,185
Case costs and expenses (estimated) −$18,000
Estimated net to plaintiff ~$280,315

This is a purely hypothetical illustration. Actual fees, costs, and settlement amounts will vary. Consult your specific retainer agreement for exact terms.

The net-to-plaintiff figure is a reality that many potential plaintiffs do not fully appreciate when they first learn about projected settlement ranges. A $475,000 gross settlement typically yields $280,000 to $300,000 to the plaintiff after fees and costs. This is still a substantial recovery for many plaintiffs, particularly for Tier 3 cases where gross settlements may be closer to $200,000 — netting somewhere in the $120,000 to $140,000 range depending on costs. Understanding this math helps set realistic expectations.

Why Settlements Haven't Happened Yet — The Mass Tort Timeline

The absence of settlements as of April 2026 is not a sign that the litigation is faltering or that Pfizer is in a strong position. It reflects the normal, predictable timeline of mass tort litigation, which follows a well-established sequence of events before defendants typically engage in serious settlement discussions.

February 7, 2025

MDL Centralized Before Judge Rodgers

Cases consolidated in Northern District of Florida, Pensacola Division. MDL leadership appointed (Christopher Seeger, Bryan Aylstock, Ellen Relkin).

December 17, 2025

FDA Approves Meningioma Warning

FDA adds meningioma warning to Depo-Provera label — the single most important regulatory event in the litigation. Case filings doubled in four months following this development.

January 27, 2026

Pretrial Order No. 30 Issued

Court ruled that preemption and Daubert rulings will apply simultaneously to all MDL cases — making both rulings existential for the litigation as a whole.

May 29, 2026 — Upcoming

Daubert Challenge Briefs Due

Both parties submit expert admissibility arguments. Pfizer will argue plaintiff scientists should not be allowed to testify; plaintiffs will challenge Pfizer's defense experts.

June 24–26, 2026 — Critical

General Causation Daubert Hearing

Three-day hearing before Judge Rodgers to determine whether plaintiff scientists can testify that Depo-Provera causes meningioma. A ruling in plaintiffs' favor is essential for the litigation to proceed to trial. If this hearing goes well, an estimated 10,000 warehoused claims are expected to be filed immediately, flooding the docket and dramatically increasing Pfizer's exposure.

Pending

Preemption Ruling

Judge Rodgers must rule on Pfizer's federal preemption defense. A ruling against preemption would eliminate Pfizer's primary legal shield, paving the way for failure-to-warn claims to proceed to juries.

December 7–14, 2026

First Bellwether Trial: Blonski v. Pfizer

The first jury to hear a Depo-Provera meningioma case renders a verdict. This is the event that typically triggers serious settlement negotiations in mass tort litigations. A substantial plaintiff verdict would create enormous pressure on Pfizer to resolve the 3,490+ pending cases (and potentially 10,000+ warehoused cases) without trial.

2027 — Expected

Settlement Negotiations / Additional Bellwether Trials

Depending on the December 2026 outcome, serious settlement negotiations could begin in early 2027. Four additional bellwether trials are expected in January 2027, which will further inform both sides' negotiating positions.

The 10,000 warehoused unfiled claims deserve specific attention because they represent a unique form of leverage. Judge Rodgers has ordered plaintiff leadership to disclose the scope of these unfiled inventories — indicating the court is aware of their existence and their potential to overwhelm the docket. Once favorable Daubert and preemption rulings come through, those 10,000 cases can be filed almost simultaneously, presenting Pfizer with the prospect of defending not 3,500 cases but 13,500+ cases. The cost of litigating that many cases to verdict would be staggering — and the practical pressure to settle would become near-irresistible.

Don't wait for settlement talks to begin

The most critical thing you can do right now is get on record with an attorney before the bellwether trial. It costs nothing to evaluate your claim — and waiting could put you at risk of missing the statute of limitations.

Check Your Eligibility — Free arrow_forward

Pfizer's Financial Exposure and Capacity to Settle

One question potential plaintiffs frequently ask is whether the defendant has the financial capacity to pay out substantial settlements. With Pfizer, the answer is unambiguous: yes, by any measure.

$150B+

Pfizer market capitalization

$63.6B

Pfizer annual revenue (2023)

$2M+

Prior Depo-Provera bone density case settlements

Pfizer is among the largest pharmaceutical companies in the world, with a market capitalization exceeding $150 billion and decades of experience managing large-scale pharmaceutical litigation. The company has settled numerous mass tort cases historically and has the financial infrastructure to administer large settlement programs. Financial capacity is not a limiting factor in this litigation.

A useful precedent comes from Pfizer's own history with Depo-Provera. The company previously settled bone density injury claims arising from long-term Depo-Provera use — the same drug, different injury — for amounts reported to exceed $2 million in individual cases.[5] These prior bone density settlements demonstrate that Pfizer has settled Depo-Provera cases before, that it has a legal team experienced in evaluating these claims, and that the company has paid at the upper end of mass tort settlement ranges for particularly severe injuries involving this specific medication.

The meningioma litigation presents a different injury category than the bone density cases, but the precedent of Pfizer settling Depo-Provera claims at meaningful dollar amounts is relevant. Plaintiff attorneys cite those prior settlements when arguing that Pfizer is capable of and willing to pay substantial values for serious injuries connected to this drug — if the litigation reaches the point where settlement makes more financial sense than continued defense costs.

If the December 2026 bellwether results in a substantial plaintiff verdict and the warehoused claims are filed, Pfizer would be facing potential liability exposure running into the tens of billions of dollars if every case went to trial and resulted in verdicts at Tier 1 and Tier 2 projected values. That exposure calculation — even heavily discounted for litigation risk — creates enormous incentive for settlement.

What You Can Do Now to Maximize Your Case Value

The strongest Depo-Provera claims are the best-documented ones. Regardless of where the litigation currently stands, there are concrete steps you can take right now that will position your case as favorably as possible when settlement negotiations eventually begin.

1. Get an MRI if You Haven't Already

If you are a long-term Depo-Provera user experiencing headaches, vision changes, hearing changes, balance problems, or cognitive symptoms, and you have not had a brain MRI, get one. Many meningiomas are slow-growing and asymptomatic for years before causing noticeable problems. An MRI is the gold standard for detecting intracranial tumors and is the first piece of medical evidence any attorney will look for. Without a confirmed imaging diagnosis, you generally do not have a case — no matter how long you used Depo-Provera.

2. Obtain All Neurologist and Oncology Records

Once a meningioma is identified, your medical records from all treating physicians — radiologists, neurologists, neurosurgeons, oncologists, and your primary care physician — become the evidentiary foundation of your case. Request complete records including MRI reports, surgical operative notes if applicable, pathology reports if a tissue biopsy was performed, and all clinical visit notes. Attorneys will need these records to evaluate your case and eventually to support your damages claims before a jury or settlement administrator.

3. Preserve All Depo-Provera Injection Records

The causal link in your case depends on demonstrating that you actually used Depo-Provera and for how long. Prescription records from your pharmacy, injection logs from the clinic or OB-GYN where you received the shots, your own appointment records, and health insurance records documenting the injections all serve this purpose. If you cannot locate records, request them from your pharmacy (which may maintain records for 7–10 years) and from any clinic where you received care. Records from college health centers, Planned Parenthood, or military health facilities may take longer to obtain but are equally valid.

4. Start Documenting Symptoms Over Time

A contemporaneous symptom diary — kept regularly and dating from your diagnosis — becomes powerful evidence of the impact the meningioma has had on your daily life. Note specific symptoms, their frequency and severity, activities you can no longer perform, changes in your mood or personality that family and friends have observed, work limitations, and the emotional toll of your diagnosis and treatment. Courts and juries respond to evidence of concrete, documented suffering. A symptom diary kept from this point forward, combined with medical records documenting neurological deficits, significantly strengthens your non-economic damages argument.

5. Consult an Attorney as Soon as Possible

This is not merely a marketing point — it is a practical legal reality. Statutes of limitations vary by state (from one year in Kentucky, Louisiana, and Tennessee to three or more years in many other states), and while the discovery rule may extend your filing deadline, it is not guaranteed and must be argued affirmatively. The most conservative and safe approach is to consult an attorney now, file your claim to preserve it, and gather documentation while the case proceeds through pre-trial. Waiting carries real risk: records degrade, witnesses' memories fade, and some state courts apply strict limitations constructions. Filing early costs you nothing. Missing the deadline could cost you everything.

A Note on Waiting

Some potential plaintiffs are tempted to wait until settlements are announced to see what the numbers look like before deciding whether to file. This is strategically risky. Settlement grid values are typically locked in for plaintiffs who are already represented and enrolled in the settlement program. Those who contact an attorney only after a settlement is announced may find that the enrollment window has closed or that their case cannot be accepted in time to participate. Early participation in a mass tort settlement program almost always produces better outcomes than late participation.

Frequently Asked Questions

How much is the Depo-Provera lawsuit worth? expand_more

Attorney projections estimate individual Depo-Provera settlement values ranging from under $150,000 for minimal injuries (asymptomatic tumors requiring no treatment) to $650,000–$1,500,000 or more for cases involving Grade II or III tumors, multiple surgeries, and significant permanent neurological deficits such as vision loss, hearing loss, cognitive impairment, or seizure disorders. Cases requiring a single craniotomy with partial neurological deficits are estimated at $300,000–$650,000. Cases managed without surgery (radiation or watchful waiting) fall in the $150,000–$300,000 range. These are projections only — no actual settlements have been finalized as of April 2026, and final amounts will depend on litigation outcomes and Pfizer's negotiating posture.

Has Pfizer settled the Depo-Provera lawsuit yet? expand_more

No. As of April 2026, Pfizer has not settled any Depo-Provera meningioma cases and has not publicly acknowledged liability. The MDL is in active pre-trial proceedings with a Daubert hearing on general causation scheduled for June 24–26, 2026, a preemption ruling pending, and the first bellwether trial (Blonski v. Pfizer) scheduled for December 7–14, 2026. Mass tort settlements typically occur after bellwether trial results give both sides hard data on jury sentiment — meaning meaningful settlement negotiations are unlikely before early 2027 at the earliest.

What factors determine how much a Depo-Provera case is worth? expand_more

The primary factors are: WHO tumor grade (I, II, or III — higher grades support higher values), whether surgery (craniotomy) was required and how many surgeries took place, severity and permanence of neurological deficits such as vision loss, hearing loss, cognitive impairment, or seizure disorders, duration of Depo-Provera use (longer use strengthens the causation argument — the BMJ study found 5.55x odds ratio for 1+ year users), age at first use, documented lost income and economic damages including lost future earning capacity, pain and suffering documentation through medical records and symptom diaries, and caregiver and ongoing treatment costs. Cases with strong documentation across all of these factors command the highest projected values.

How do Depo-Provera settlement projections compare to other drug lawsuits? expand_more

The Yaz/Yasmin blood clot litigation (Bayer) paid approximately $212,000–$220,000 per claimant across 10,300 cases totaling $2.04 billion. NuvaRing (Merck, blood clots) resolved at roughly $50,000 per claim across 2,000 cases. Essure (Bayer, device complications) averaged about $41,000 per claim across 39,000 cases. Talcum powder (J&J, ovarian cancer) produced individual jury verdicts exceeding $2 billion in some cases. Attorneys argue that meningioma brain tumors are categorically more severe injuries than blood clots or device complications — supporting higher per-case values in the Depo-Provera litigation compared to most prior pharmaceutical mass tort settlements.

When will Depo-Provera settlements be finalized? expand_more

No firm timeline exists. The earliest realistic window for serious settlement negotiations to begin is early 2027, following the December 7–14, 2026 Blonski v. Pfizer bellwether trial. Key pre-settlement milestones include the June 24–26, 2026 Daubert hearing on causation (which determines whether plaintiffs' scientific experts can testify) and the pending preemption ruling. If favorable rulings cause the estimated 10,000 warehoused unfiled claims to be filed simultaneously, the resulting docket pressure on Pfizer could dramatically accelerate settlement discussions. Mass tort resolutions often take years from the bellwether trial, so plaintiffs should prepare for a 2027–2029 resolution timeframe as a realistic expectation.

Sources & References

  1. [1] MDL Update. Depo-Provera MDL No. 3140 Case Count Tracker (April 5, 2026). — https://mdlupdate.com/mdl/3140-depo-provera/
  2. [2] U.S. District Court, Northern District of Florida. In re: Depo-Provera Products Liability Litigation, MDL No. 3140 — Case Management and Pretrial Orders. — https://www.flnd.uscourts.gov
  3. [3] Roland N, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024; doi: 10.1136/bmj-2023-078078. — https://pubmed.ncbi.nlm.nih.gov/38537944/
  4. [4] TriNetX / JAMA Neurology. Depot Medroxyprogesterone Acetate and Risk of Meningioma in the U.S. (TriNetX Database, December 2004–December 2024). November 2025. — https://pubmed.ncbi.nlm.nih.gov/40892397/
  5. [5] Legal reporting: Pfizer prior Depo-Provera bone density litigation settlements. See: Drugwatch Depo-Provera litigation history. — https://www.drugwatch.com/depo-provera/lawsuit/
  6. [6] NBC News. FDA Approves Label Change for Depo-Provera, Adding Brain Tumor Warning (December 17, 2025). — https://www.nbcnews.com
  7. [7] FDA. Depo-Provera CI Prescribing Information, Revised December 2025 — NDA 020246s074. — https://www.accessdata.fda.gov
  8. [8] University of British Columbia. Depot Medroxyprogesterone Acetate and Risk of Meningioma: A Population-Based Cohort Study (72,181 users vs. 247,180 controls). May 2025.
  9. [9] Seeger Weiss LLP. MDL Leadership Appointments and Case Management Summaries. — https://www.seegerweiss.com
  10. [10] Reuters / AP. Historical Pharmaceutical Mass Tort Settlements: Yaz/Yasmin, NuvaRing, Essure (settlement documentation and reporting, 2013–2022).
edit_note

SuperLawsuits Editorial Team

Reviewed by licensed attorneys in our network · Last updated April 29, 2026

More on the Depo-Provera Lawsuit

Continue reading our coverage of this rapidly evolving litigation.

gavel Depo-Provera Lawsuit — Check If You May Qualify chevron_right article Depo-Provera Lawsuit April 2026 Update: 3,490 Cases, FDA Warning & First Trial Set chevron_right article Who Qualifies for the Depo-Provera Lawsuit? Eligibility Criteria Explained chevron_right article Depo-Provera Meningioma Symptoms: Warning Signs Every User Should Know chevron_right